Hospira enters angry-investor phase of remediation

Hospira ($HSP) shareholders claim the company didn't disclose the extent of problems at its North Carolina plant. Yet CEO Michael Ball admitted in October 2011 that the remediation job was "bigger than we thought." Nonetheless, the ailing generics-maker is now dealing with class action lawsuits over what it didn't mention about GMP problems while crowing about its efficiency and cost-cutting program. Hospira is in good company: Johnson & Johnson ($JNJ), Genzyme and Caraco each faced investor lawsuits along their remediation journeys. Story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.